Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis

This study, using a 10-year clinical and administrative dataset, did not find any increased risk of relapse after IVF. The maintenance of disease-modifying therapies until IVF was a determining factor in reducing the risk of relapse.

Authors

Institutions

Publication Details

Journal
Neurology Neuroimmunology & Neuroinflammation
Published
2025-02-11
DOI
https://doi.org/10.1212/nxi.0000000000200371
Citations
4
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
5.89

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis

Emmanuelle Le Page, Bruno Stankoff, Jonathan Ciron, Corinne Pottier et al.
4 citations
Neurology Neuroimmunology & Neuroinflammation
Multiple Sclerosis Research Studies
5.89
article

Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis

Emmanuelle Le Page, Bruno Stankoff, Jonathan Ciron, Corinne Pottier, Gilles Defer, Pierre Labauge, Jerome De Seze, Abdullatif Al Khedr, Thibault Moreau, Sandra Vukusic, Bertrand Bourre, Abir Wahab, Élisabeth Maillart, Aurélie Ruet, Romain Casey, Pierre Clavelou, Jean Marc Pelletier, Anne Kerbrat, David Axel Laplaud, Hélène Zéphir, Marie Mainguy, Éric Thouvenot, Mariana Sarov, Amélie Dos Santos, Christine Lebrun‐Frénay, Laure Michel, Emmanuelle Leray, Laurent Magy, Solène Moulin, Karolina Hankiewicz, Inès Doghri, Eric Berger, Éric Manchon
article en
4 citations

Abstract

This study, using a 10-year clinical and administrative dataset, did not find any increased risk of relapse after IVF. The maintenance of disease-modifying therapies until IVF was a determining factor in reducing the risk of relapse.

Neurology Neuroimmunology & NeuroinflammationVol. 12(2)
Université Claude Bernard Lyon 1 (FR), Centre National de la Recherche Scientifique (FR), Allen Institute for Brain Science (US), Université Toulouse III - Paul Sabatier (FR), Université de Bordeaux (FR), Inserm (FR), École des Hautes Études en Santé Publique (FR), Université Fédérale de Toulouse Midi-Pyrénées (FR), Université Clermont Auvergne (FR), Université de Montpellier (FR), Université de Lille (FR), Multiple Sclerosis Foundation (US), Centre Hospitalier Universitaire de Lille (FR), Centre Hospitalier Universitaire de Nice (FR), Centre Hospitalier Universitaire de Nantes (FR), Centre Hospitalier Universitaire de Toulouse (FR), Sorbonne Université (FR), Centre Hospitalier Universitaire de Besançon (FR), Centre de Recherche en Neurosciences de Lyon (FR), Centre Hospitalier Universitaire de Tours (FR), Centre Hospitalier Universitaire Amiens-Picardie (FR), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Bretonneau (FR), Hospices Civils de Lyon (FR), Observatoire Français de la Sclérose en Plaques (FR), Hôpital Pierre Wertheimer (FR), Centre Hospitalier Universitaire de Reims (FR), Centre Hospitalier Universitaire de Caen Normandie (FR), CHU Dijon Bourgogne (FR), CIC Rennes (FR), Centre Hospitalier Universitaire de Limoges (FR), Pitié-Salpêtrière Hospital (FR), Centre Hospitalier de Gonesse (FR), Centre Jean Bernard (FR), Neurocentre Magendie (FR), Centre d'Investigation Clinique de Nantes (FR), Hôpitaux Universitaires Henri-Mondor (FR), Centre Hospitalier Saint-Denis (FR), Infinity (United States) (US), Institut du Cerveau (FR), Centre Hospitalier Universitaire de Rouen (FR), Centre Hospitalier Universitaire de Rennes (FR), Hôpital Dupuytren (FR), Hôpital de la Timone (FR), Bicêtre Hospital (FR), Arènes: politique, santé publique, environnement, médias (FR), Université de Rennes (FR), Université de Rouen Normandie (FR), Université de Nîmes (FR), Université de Reims Champagne-Ardenne (FR), Université de Caen Normandie (FR)
Sanofi, Biogen, Teva Pharmaceutical Industries, Alexion Pharmaceuticals, Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques, Argenx, Agence Nationale de la Recherche, École des Hautes Études en Santé Publique, Conservatoire National des Arts et Métiers, MedDay Pharmaceuticals
Openalex Percentile: Top 5%
Multiple Sclerosis Research Studies
5.89
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.